MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Peregrine Pharmaceuticals Company Profile (NASDAQ:PPHM)

Consensus Ratings for Peregrine Pharmaceuticals (NASDAQ:PPHM) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.75 (336.05% upside)

Analysts' Ratings History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Show:
DateFirmActionRatingPrice TargetActions
1/22/2016Roth CapitalReiterated RatingBuy$3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/14/2016FBR & Co.Reiterated RatingOutperform$3.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/12/2016FBR & Co.Initiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/14/2015Noble FinancialReiterated RatingBuy$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2015FBR & Co.Reiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/25/2015Roth CapitalReiterated RatingBuy$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/16/2015Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/16/2015Noble FinancialInitiated CoverageBuy$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/10/2015Roth CapitalSet Price TargetBuy$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2015MLV & Co.Reiterated RatingBuy$3.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2015Roth CapitalSet Price TargetBuy$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/13/2015MLV & Co.Set Price TargetBuy$3.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/15/2014Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2014MLV & Co.Boost Price TargetBuy$2.50 -> $3.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 2/10/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by the American Association of Individual Investors As Featured by Seeking Alpha